La réalisation systématique de l’imagerie par résonance magnétique cérébrale a-t-elle un intérêt chez l’enfant atteint de neurofibromatose de type 1 ?
G. Blanchard(Hôpital Femme Mère Enfant), Launay Francois(Hôpital Femme Mère Enfant), Christophe Rousselle(Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail), Sylvie Lorthois(Centre National de la Recherche Scientifique), M. Bernard(Institut NeuroMyoGène), P. Combemale(Centre Léon Bérard), S. Pinson(Hôpital Edouard Herriot)
Cited by 7
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
|Orphanet Journal of Rare Diseases|2020|188